rosiglitazone has been researched along with Psoriasis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chi, CC; Lee, CY; Liu, CY; Tien O'Donnell, F; Tung, TH; Wang, SH | 1 |
| Choi, ET; Hu, W; Nanayakkara, GK; Shao, Y; Wang, H; Xu, K; Yang, F; Yang, WY; Yang, X | 1 |
| Garl, PJ; Han, G; Li, AG; Salter, K; Wang, XJ; Williams, CA | 1 |
| Kuenzli, S; Saurat, JH | 1 |
| Avery, MA; Benson, SC; Bhagavathula, N; Chittiboyina, A; Ellis, CN; Ho, CI; Kurtz, TW; Lal, A; Nerusu, KC; Pershadsingh, HA; Varani, J | 1 |
| Friedmann, PS; Krentz, AJ | 1 |
| Barker, JN; Daly, S; Ellis, CN; Haig, AE; Jayawardene, DA; Parker, CA | 1 |
2 review(s) available for rosiglitazone and Psoriasis
| Article | Year |
|---|---|
Effects of antidiabetic drugs on psoriasis: A meta-analysis.
Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Pioglitazone; Psoriasis; Rosiglitazone; Treatment Outcome | 2021 |
A role for TGFbeta signaling in the pathogenesis of psoriasis.
Topics: Animals; Epidermis; Humans; Immune System; Inflammation; Keratinocytes; Mice; Mice, Transgenic; Psoriasis; Rosiglitazone; Signal Transduction; Skin; Skin Physiological Phenomena; Thiazolidinediones; Transforming Growth Factor beta; Transgenes | 2010 |
2 trial(s) available for rosiglitazone and Psoriasis
| Article | Year |
|---|---|
Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Female; Free Radical Scavengers; Humans; Male; Middle Aged; Pilot Projects; Psoriasis; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfides; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome; Vasodilator Agents | 2003 |
Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone.
Topics: Adolescent; Adult; Aged; C-Reactive Protein; Chronic Disease; Dermatologic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Placebo Effect; Psoriasis; Rosiglitazone; Severity of Illness Index; Thiazolidinediones | 2007 |
3 other study(ies) available for rosiglitazone and Psoriasis
| Article | Year |
|---|---|
GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg.
Topics: Animals; Antigen-Presenting Cells; Aorta; Cell Plasticity; Endothelial Cells; GATA3 Transcription Factor; Histone Deacetylase 6; Humans; Insulin Resistance; Lupus Erythematosus, Systemic; Lymphocyte Activation; Mice; Mice, Knockout, ApoE; Proto-Oncogene Proteins c-bcl-6; Psoriasis; Rosiglitazone; T-Lymphocytes, Regulatory; Th1 Cells | 2018 |
Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes.
Topics: Adult; Cell Division; Cell Movement; Cells, Cultured; Epidermal Cells; Fibroblasts; Humans; Hypoglycemic Agents; Keratinocytes; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Organ Culture Techniques; Pioglitazone; Psoriasis; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2004 |
Type 2 diabetes, psoriasis and thiazolidinediones.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Psoriasis; Rosiglitazone; Thiazolidinediones | 2006 |